Abstract 216P
Background
Wilms tumor (WT) is a rare kidney cancer, but it is the most common malignant tumor of the kidneys of children. Although radical nephroectomy has been viewed as the gold standard surgery in Wilms tumor management for many years, partial nephrectomy has gained a lot of attention recently. So we conducted this study to compare the long term overall survival between those two different surgical techniques.
Methods
Using SEER database, we extracted the data of 636 patients with WT from 2000 to 2006. There were 55 (8.6%) patients underwent partial nephrectomy, while 581 (91.4%) of them underwent radical nephrectomy. Patients’ demographics were assessed.
Results
Our study showed that there is NO significant difference in Long-Term overall survival between partial nephrectomy and radical nephrectomy, where overall 10-year relative survival rates were 92.6% and 88.1%, respectively (p value =0.240). Subgroup analysis revealed NO significant difference in overall survival Except in patients with different age groups as seen in the table (p value <0.0001) but this could have been caused by the fact that few patients were recorded.
Table: 216P
Variables | Survival of Patients | p value | |
---|---|---|---|
Partial nephroectomy | Radical nephroectomy | ||
Sex Male Female | 96 % 89.7 % | 87.9 % 88.3 % | 0.821 |
Age 0- 9 10-19 20-39 40-59 60-79 | 91.5% 100%** 100%** 100%** 100%** | 89.9% 71.8% 36.4% 100% 66.7% | <0.0001*** |
Race White | 91% 100% _* % _* % | 88.8% 86.1% 88.9% 83.3% | 0.574 |
Black American Indian/Alaska Asian/pacific Islander | |||
Laterality Right left Bilateral | 89.9% 92.9% 95% | 90.1% 85.8% 92% | 0.175 |
Highly significant P-value ≤ 0.001.
**few no. of cases _.
*no recorded patients.
Conclusions
There is NO significant difference in overall 10-year survival between partial nephrectomy and radical nephrectomy. So, we recommend the application of partial nephrectomy in the appropriate patients to preserve as much kidney tissue and function as possible especially in bilateral WT. Further studies should be conducted on larger number of patients and they should study the efficacy of chemotherapy in patients undergoing partial nephrectomy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Mira Mohamed Mostafa.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
133P - Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
134P - Identification, development and validation of a circulating miRNA-based diagnostic signature for early detection of gastric cancer
Presenter: Daisuke Izumi
Session: Poster display session
Resources:
Abstract
135P - The promising key genes associated with tumour microenvironment and prognosis of hepatocellular carcinoma
Presenter: Jing Fang
Session: Poster display session
Resources:
Abstract
136P - Helicobacter pylori-positive gastric diffuse large B-cell lymphoma: A subset with distinct prognostic features
Presenter: Yuan Cheng
Session: Poster display session
Resources:
Abstract
137P - Significant benefit of pyrotinib combined with SHR6390 in patients with multiline-resistant HER2-positive advanced gastric cancer
Presenter: Zuhua Chen
Session: Poster display session
Resources:
Abstract
138P - Incidence of supracarinal lymph node positivity in operated cases of total esophagectomy: Short term results from a tertiary cancer centre
Presenter: Akhil Palod
Session: Poster display session
Resources:
Abstract
139P - Prognostic usefulness of advanced lung cancer inflammation index in locally-advanced pancreatic carcinoma patients treated with radical chemoradiotherapy
Presenter: Ayberk Besen
Session: Poster display session
Resources:
Abstract
140P - Pancreaticoduodenectomy versus combined neoadjuvant chemotherapy and pancreaticoduodenectomy: Survival patterns among patients with stage II & III periampullary carcinoma
Presenter: Mai Abdelkader
Session: Poster display session
Resources:
Abstract
141P - A 13-gene signature of DNA repair predicts prognosis in gastric cancer patients
Presenter: Jinjia Chang
Session: Poster display session
Resources:
Abstract
142P - Relation between Interleukin -4 (590C/T) gene polymorphism and hepatocellular carcinoma risk in HBV and HCV patients
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract